232 related articles for article (PubMed ID: 17456618)
1. Malignancies in renal transplantation: an unmet medical need.
Dantal J; Pohanka E
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i4-10. PubMed ID: 17456618
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
3. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Kauffman HM; Cherikh WS; McBride MA; Cheng Y; Hanto DW
Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677
[TBL] [Abstract][Full Text] [Related]
5. Cancers after renal transplantation.
Wong G; Chapman JR
Transplant Rev (Orlando); 2008 Apr; 22(2):141-9. PubMed ID: 18631867
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
7. A population-based study of skin cancer incidence and prevalence in renal transplant recipients.
Moloney FJ; Comber H; O'Lorcain P; O'Kelly P; Conlon PJ; Murphy GM
Br J Dermatol; 2006 Mar; 154(3):498-504. PubMed ID: 16445782
[TBL] [Abstract][Full Text] [Related]
8. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
[TBL] [Abstract][Full Text] [Related]
9. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
10. [Hypertension after kidney transplantation].
Racki S
Lijec Vjesn; 2006; 128(11-12):373-8. PubMed ID: 17212200
[TBL] [Abstract][Full Text] [Related]
11. [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
Végso G
Magy Onkol; 2009 Jun; 53(2):149-56. PubMed ID: 19581181
[TBL] [Abstract][Full Text] [Related]
12. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
Crespo-Leiro MG; Alonso-Pulpón L; Arizón JM; Almenar L; Delgado JF; Palomo J; Manito N; Rábago G; Lage E; Diaz B; Roig E; Pascual D; Blasco T; de la Fuente L; Campreciós M; Vázquez de Prada JA; Muñiz J
J Heart Lung Transplant; 2007 Nov; 26(11):1105-9. PubMed ID: 18022075
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for malignancy in Japanese renal transplant recipients.
Imao T; Ichimaru N; Takahara S; Kokado Y; Okumi M; Imamura R; Namba Y; Isaka Y; Nonomura N; Okuyama A
Cancer; 2007 May; 109(10):2109-15. PubMed ID: 17407138
[TBL] [Abstract][Full Text] [Related]
14. Excess risk of cancer in renal transplant patients.
Kessler M; Jay N; Molle R; Guillemin F
Transpl Int; 2006 Nov; 19(11):908-14. PubMed ID: 17018126
[TBL] [Abstract][Full Text] [Related]
15. [Lymphoproliferative syndromes after cardiac transplantation and treatment with cyclosporine. Report of 4 cases].
Guerci AP; Burtin P; Mattei S; Lederlin P
Ann Med Interne (Paris); 1992; 143(3):155-9. PubMed ID: 1524349
[TBL] [Abstract][Full Text] [Related]
16. Urological malignancy after renal transplantation.
Besarani D; Cranston D
BJU Int; 2007 Sep; 100(3):502-5. PubMed ID: 17669141
[TBL] [Abstract][Full Text] [Related]
17. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
18. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation.
Dharnidharka VR; Stevens G
Pediatr Transplant; 2005 Oct; 9(5):622-6. PubMed ID: 16176420
[TBL] [Abstract][Full Text] [Related]
19. [Cancer after kidney transplantation].
Sandrini S; Setti G; Bossini N; Maiorca P
G Ital Nefrol; 2004; 21 Suppl 26():S67-73. PubMed ID: 15732048
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk factors in renal transplantation--current controversies.
Marcén R
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii3-8. PubMed ID: 16815854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
